PMID- 35357586
OWN - NLM
STAT- MEDLINE
DCOM- 20220720
LR  - 20220721
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 148
IP  - 8
DP  - 2022 Aug
TI  - Upregulated LINC01088 facilitates malignant phenotypes and immune escape of 
      colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
PG  - 1965-1982
LID - 10.1007/s00432-022-03981-8 [doi]
AB  - PURPOSE: Long intergenic non-coding RNA LINC01088 is a newly discovered long 
      non-coding RNA (lncRNA). Its biological function in colorectal cancer (CRC) 
      remains unknown. METHODS: Here, 36 paired CRC and para-cancerous tissues were 
      collected. In vitro, fluorescence in situ hybridization (FISH) assay, qPCR, 
      western blotting analysis and cellular functional experiments, RNA 
      immunoprecipitation (RIP) assay and dual-luciferase reporter system analysis were 
      performed. In vivo, xenograft tumor mouse models were generated. Besides, 
      patient-derived intestinal organoid (PDO) was generated ex vivo. RESULTS: We 
      found that LINC01088 was significantly upregulated in colorectal cancer tissues 
      and CRC cell lines compared to adjacent normal tissues and colonic epithelial 
      cells. High LINC01088 levels were correlated with adverse outcomes in patients 
      with CRC. LINC01088 was mainly located in the cytoplasm. LINC01088 knockdown 
      suppressed the proliferation, migration, invasion, and immune escape of 
      colorectal cancer cells. Mechanistically, LINC01088 bound directly to miR-548b-5p 
      and miR-548c-5p that were significantly upregulated Ras GTPase-activating 
      protein-binding proteins 1 (G3BP1) and programmed death ligand 1 (PD-L1) 
      expression, altering CRC cell phenotypes. In mouse xenograft models, LINC01088 
      knockdown restrained CRC tumor growth and lung metastasis. Furthermore, G3BP1 
      overexpression reversed LINC01088-knockdown-mediated inhibitory effects on tumor 
      growth. Notably, LINC01088 knockdown downregulated PD-L1 expression, while G3BP1 
      overexpression restored PD-L1 expression in xenograft tumors. Besides, LINC01088 
      knockdown repressed CRC organoid growth ex vivo. CONCLUSION: Overall, these 
      findings suggested that LINC01088 directly targeted miR-548b-5p and miR-548c-5p, 
      promoting G3BP1 and PD-L1 expression, which facilitated colorectal cancer 
      progression and immune escape.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Li, Chenmeng
AU  - Li C
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
FAU - Pan, Bei
AU  - Pan B
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
FAU - Wang, Xuhong
AU  - Wang X
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
FAU - Liu, Xiangxiang
AU  - Liu X
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
FAU - Qin, Jian
AU  - Qin J
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
FAU - Gao, Tianyi
AU  - Gao T
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
AD  - Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing 
      Medical University, Nanjing, 211100, Jiangsu, China.
FAU - Sun, Huiling
AU  - Sun H
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China.
AD  - Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing 
      Medical University, Nanjing, 211100, Jiangsu, China.
FAU - Pan, Yuqin
AU  - Pan Y
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China. 
      panyuqin01@163.com.
AD  - Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing 
      Medical University, Nanjing, 211100, Jiangsu, China. panyuqin01@163.com.
FAU - Wang, Shukui
AU  - Wang S
AUID- ORCID: 0000-0001-6972-2587
AD  - School of Medicine, Southeast University, Nanjing, 210009, Jiangsu, China. 
      sk_wang@njmu.edu.cn.
AD  - General Clinical Research Center, Nanjing First Hospital of Nanjing Medical 
      University, No. 68, Changle Road, Nanjing, 210006, Jiangsu, China. 
      sk_wang@njmu.edu.cn.
AD  - Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing 
      Medical University, Nanjing, 211100, Jiangsu, China. sk_wang@njmu.edu.cn.
LA  - eng
GR  - 81972806/National Natural Science Foundation of China/
GR  - 81802093/National Natural Science Foundation of China/
GR  - 82002230/National Natural Science Foundation of China/
GR  - BE2019614/Jiangsu Provincial Key Research and Development Plan/
GR  - LR2021017/Elderly Health Research Project of Jiangsu Province/
GR  - NMUC2020035/Specialized Cohort Research Project of Nanjing Medical University/
PT  - Journal Article
DEP - 20220331
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (B7-H1 Antigen)
RN  - 0 (MIRN548 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - 0 (RNA Recognition Motif Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - EC 3.6.4.12 (G3BP1 protein, human)
RN  - EC 3.6.4.13 (RNA Helicases)
SB  - IM
MH  - Animals
MH  - B7-H1 Antigen/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - *Colorectal Neoplasms/pathology
MH  - DNA Helicases/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Mice
MH  - *MicroRNAs/genetics
MH  - Phenotype
MH  - Poly-ADP-Ribose Binding Proteins/genetics
MH  - RNA Helicases/genetics/metabolism
MH  - RNA Recognition Motif Proteins/genetics/metabolism
MH  - *RNA, Long Noncoding/genetics
OTO - NOTNLM
OT  - Colorectal cancer
OT  - Immune escape
OT  - LINC01088
OT  - PD-L1
OT  - microRNAs
EDAT- 2022/04/01 06:00
MHDA- 2022/07/22 06:00
CRDT- 2022/03/31 12:06
PHST- 2022/01/13 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/01 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/03/31 12:06 [entrez]
AID - 10.1007/s00432-022-03981-8 [pii]
AID - 10.1007/s00432-022-03981-8 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2022 Aug;148(8):1965-1982. doi: 
      10.1007/s00432-022-03981-8. Epub 2022 Mar 31.